Trials / Completed
CompletedNCT00468312
Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis (Study P05106)(COMPLETED)
Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 429 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to assess the effectiveness of mometasone furoate nasal spray (MFNS) once daily compared with placebo in subjects with seasonal allergic rhinitis (SAR) in reducing the total symptom score.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mometasone furoate nasal spray | Two sprays (50 mcg/spray) in each nostril (200 mcg daily) in the morning |
| DRUG | Placebo | Two sprays in each nostril in the morning |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2007-07-01
- Completion
- 2007-07-01
- First posted
- 2007-05-02
- Last updated
- 2022-02-09
- Results posted
- 2010-06-22
Source: ClinicalTrials.gov record NCT00468312. Inclusion in this directory is not an endorsement.